Pharmacogenomics to Revive Drug Development in Cardiovascular Disease

被引：6

作者：

Dube, Marie-Pierre ^{[1
,2
,3
]}

de Denus, Simon ^{[2
,4
]}

Tardif, Jean-Claude ^{[2
,3
]}

机构：

[1] Montreal Heart Inst, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada

[2] Univ Montreal, Beaulieu Saucier Pharmacogen Ctr, Montreal, PQ, Canada

[3] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada

[4] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 2016年 / 30卷 / 01期

关键词：

Cardiovascular; Drug discovery; Pharmacogenomics; Personalized medicine; Mendelian randomization; INTERLEUKIN-6 RECEPTOR PATHWAYS; CORONARY-HEART-DISEASE; SURROGATE END-POINTS; MENDELIAN RANDOMIZATION; PCSK9; CHOLESTEROL; PREVENTION; EVENTS; TRIAL; RISK;

D O I：

10.1007/s10557-015-6637-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at an earlier stage and by enabling more efficient outcomes trials. This article will review some of the recent developments highlighting the value of pharmacogenomics for drug development. We discuss how genetic biomarkers can enable the conduct of more efficient clinical outcomes trials by enriching patient populations for good responders to the medication. In addition, we assess past drug development programs which support the added value of selecting drug targets that have established genetic evidence supporting the targeted mechanism of disease. Finally, we discuss how pharmacogenomics can provide valuable evidence linking a drug target to clinically relevant outcomes, enabling novel drug discovery and drug repositioning opportunities.

引用

页码：59 / 64

页数：6

共 46 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2]

[Administration FaD U.S. Department of Health and Human Services FaDA], 2013, CLIN PHARM PREM EV E

[3]

Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.017, 10.1161/CIR.0000000000000134, 10.1016/j.jacc.2014.10.011, 10.1016/j.jacc.2014.09.016]

[4]

[Anonymous], 1989, NEW ENGL J MED, V321, P406

[5]

[Anonymous], 1997, N. Engl J Med, V337, P1118

[6] Phase II and Phase III attrition rates 2011-2012 [J].